Genetic testing and counseling for the unexplained epilepsies: An evidence‐based practice guideline of the National Society of Genetic Counselors. Issue 2 (24th October 2022)

• Record Type: Journal Article
• Authors: Smith, Lacey; Malinowski, Jennifer; Ceulemans, Sophia; Peck, Katlin; Walton, Nephi; Sheidley, Beth Rosen; Lippa, Natalie
• Is Part Of: Journal of genetic counseling. Volume 32:Issue 2(2023)
• Page Start: 266
• Page End: 280
• Publication Date: 2022-10-24
• Subjects: epilepsy -- genetic counseling -- genetic testing -- practice guideline; Genetic counseling -- Periodicals; 616.042
• DOI: 10.1002/jgc4.1646
• Languages: English
• ISSNs: 1059-7700

Abstract

Abstract: Epilepsy, defined by the occurrence of two or more unprovoked seizures or one unprovoked seizure with a propensity for others, affects 0.64% of the population and can lead to significant morbidity and mortality. A majority of unexplained epilepsy (seizures not attributed to an acquired etiology, such as trauma or infection) is estimated to have an underlying genetic etiology. Despite rapid progress in understanding of the genetic underpinnings of the epilepsies, there are no recent evidence‐based guidelines for genetic testing and counseling for this population. This practice guideline provides evidence‐based recommendations for approaching genetic testing in the epilepsies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision framework. We used evidence from a recent systematic evidence review and meta‐analysis of diagnostic yield of genetic tests in patients with epilepsy. We also compiled data from other sources, including recently submitted conference abstracts and peer‐reviewed journal articles. We identified and prioritized outcomes of genetic testing as critical, important or not important and based our recommendations on outcomes deemed critical and important. We considered the desirable and undesirable effects, value and acceptability to relevant stakeholders, impact on health equity, cost‐effectiveness, certainty of evidence, and feasibility of the interventions in individuals with epilepsy. Taken together, we generated two clinical recommendations: (1) Genetic testing is strongly recommended for all individuals with unexplained epilepsy, without limitation of age, with exome/genome sequencing and/or a multi‐gene panel (>25 genes) as first‐tier testing followed by chromosomal microarray, with exome/genome sequencing conditionally recommended over multi‐gene panel. (2) It is strongly recommended that genetic tests be selected, ordered, and interpreted by a qualified healthcare provider in the setting of appropriate pre‐test and post‐test genetic counseling. Incorporation of genetic counselors into neurology practices and/or referral to genetics specialists are both useful models for supporting providers without genetics expertise to implement these recommendations.